Cambridge-based TidalSense raises €8.6 million to spread its AI-driven tech for respiratory conditions
Summary
The Cambridge-based AI-driven company has created a handheld medical device (N-Tidal) that detects changes in lung function sensitively and enables quicker, more accurate and automated diagnosis of chronic obstructive pulmonary disease (COPD), with asthma to follow. We have evaluated a broad range of propositions that involve the application of machine learning and are excited by the opportunities in the healthcare sector where we see scope to apply new tools to unmet needs. TidalSense’s solution is a prime example of where advanced machine learning techniques can be applied to deliver faster diagnostics, greater efficiencies and better patient outcomes.”, added Rea. In England alone, the NHS estimates that a third of people with hospital admissions from COPD have not been diagnosed, by which point their disease has progressed, their quality of life has deteriorated and the cost to the healthcare system has ballooned.”. That’s why we’ve developed N-Tidal, which will enable earlier, accurate detection of COPD and will result in better patient outcomes and reduced costs for healthcare environments in the long-term.”, added Patel.
Funding
Review available funding amount, funding date, investors, and linked company information related to Cambridge-based TidalSense raises €8.6 million to spread its AI-driven tech for respiratory conditions in the interactive ISVWorld profile.